Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Cerebrospinal fluid (CSF) neurofilament light (NfL) concentration has reproducibly been shown to reflect neurodegeneration in brain disorders, including Alzheimer's disease (AD). NfL concentration in blood correlates with the corresponding CSF levels, but few studies have directly compared the reliability of these 2 markers in sporadic AD. Herein, we measured plasma and CSF concentrations of NfL in 478 cognitively unimpaired (CU) subjects, 227 patients with mild cognitive impairment, and 113 patients with AD dementia. We found that the concentration of NfL in CSF, but not in plasma, was increased in response to Aβ pathology in CU subjects. Both CSF and plasma NfL concentrations were increased in patients with mild cognitive impairment and AD dementia. Furthermore, only NfL in CSF was associated with reduced white matter microstructure in CU subjects. Finally, in a transgenic mouse model of AD, CSF NfL increased before serum NfL in response to the development of Aβ pathology. In conclusion, NfL in CSF may be a more reliable biomarker of neurodegeneration than NfL in blood in preclinical sporadic AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationElastix: a toolbox for intensity-based medical image registration
Klein, S., Staring, M., Murphy, K., Viergever, M. A., & Pluim, J. (2010) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2009.2035616 · Cited by 4,311 · cited 2×
“To correct for motion and eddy-current induced distortions, all data were registered to the b 1⁄4 0 s/mm2 volume using an affine transform implemented in Elastix (Klein et al., 2010).”
MethodOakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 3×
“This coincides with the development of spatial memory deficits (Oakley et al., 2006), supporting our clinical findings that NfL in blood might be a reliable marker of axonal injury and loss first in the early symptomatic stage of AD.”
BackgroundResultInfluentialComparing correlated correlation coefficients
Meng, X.-L., Rosenthal, R., & Rubin, D. B. (1992) · Psychological Bulletin · doi:10.1037/0033-2909.111.1.172 · Cited by 2,472 · cited 1×
“For comparisons between correlation coefficients, Meng’s Z-test for correlated correlations was performed (Meng et al., 1992).”
MethodBlood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988 · cited 2×
“Neurofilament light (NfL), an intermediate filament protein expressed exclusively in neurons, has emerged as a promising blood-based biomarker of neurodegeneration in several neurological disorders, including AD (Khalil et al., 2018).”
BackgroundSelf-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 1×
“Lumbar CSF samples were collected according to a standardized protocol (Blennow et al., 2010), centrifuged for 10 minutes at 2000 g at 4 C, and aliquoted into polypropylene tubes.”
MethodSelf-citationSingle App knock-in mouse models of Alzheimer’s disease
Saito, T., Matsuba, Y., Mihira, N., Takano, J., Nilsson, P., Itohara, S., Iwata, N., & Saido, T. C. (2014) · Nature Neuroscience · doi:10.1038/nn.3697 · Cited by 1,366 · cited 1×
“To overcome this issue, the use of recently developed APP KI mice (Saito et al., 2014) would be preferable over first-generation tg mouse models for future studies.”
MethodAssociation of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K., & Initiative, F. T. A. D. N. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.6117 · Cited by 1,070 · cited 5×
“In sporadic AD, the concentrations of NfL in CSF and blood are significantly increased in both the prodromal and dementia stages of the disease, in which they associate with cognitive decline and disease-related structural brain changes (Mattsson et al., 2017; Zetterberg et al., 2016).”
InfluentialSelf-citationBiomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000
Self-citationDefining imaging biomarker cut points for brain aging and Alzheimer's disease
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Gunter, J. L., Senjem, M. L., Jones, D. T., Kantarci, K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.005 · Cited by 931
APP mouse models for Alzheimer’s disease preclinical studies.
Sasaguri, H., Nilsson, P., Hashimoto, S., Nagata, K., Saito, T., De Strooper, B., Hardy, J., Vassar, R., Winblad, B., & Saido, T. C. (2017) · The EMBO Journal · doi:10.15252/embj.201797397 · Cited by 793
Mattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H., & Blennow, K. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0765 · Cited by 726
Self-citationWhite matter changes in Alzheimer’s disease: A focus on myelin and oligodendrocytes
Nasrabady, S. E., Rizvi, B., Goldman, J. E., & Brickman, A. M. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0515-3 · Cited by 723 · cited 2×
“…(Amlien and Fjell, 2014), several studies employing neuroimaging modalities have provided evidence of both macroand microstructural white matter abnormalities during the course of the disease (Agosta et al., 2011; Liu et al., 2009; Mayo et al., 2017; Medina et al., 2006; Nasrabady et al., 2018).”
BackgroundBlood-based biomarkers for Alzheimer disease: mapping the road to the clinic
Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., Kiddle, S. J., Batrla, R., & Blennow, K. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0079-7 · Cited by 716 · cited 2×
“In recent years, the search for inexpensive and easily accessible blood-based biomarkers for monitoring of early pathological events and disease progression has intensified, given the invasiveness of lumbar puncture for CSF collection and the high cost and limited availability of positron emission tomography (PET) ima…”
BackgroundSelf-citationAlzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672
White matter changes in mild cognitive impairment and AD: a diffusion tensor imaging study
Medina, D., deToledo-Morrell, L., Urresta, F., Gabrieli, J. D. E., Moseley, M., Fleischman, D., Bennett, D. A., Leurgans, S., Turner, D. A., & Stebbins, G. T. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.03.026 · Cited by 492 · cited 1×
“Although AD has traditionally been viewed as a disease of the gray matter (Amlien and Fjell, 2014), several studies employing neuroimaging modalities have provided evidence of both macroand microstructural white matter abnormalities during the course of the disease (Agosta et al., 2011; Liu et al., 2009; Mayo et al.,…”
BackgroundZetterberg, H., Skillbäck, T., Mattsson, N., Trojanowski, J. Q., Portelius, E., Shaw, L. M., Weiner, M. W., Blennow, K., & Initiative, F. T. A. D. N. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3037 · Cited by 487 · cited 3×
“In addition, NfL in both CSF and plasma were higher in patients with MCI and AD dementia compared to CU subjects, as reported by others (Mattsson et al., 2017, 2019; Olsson et al., 2019; Zetterberg et al., 2016), suggesting that NfL tracks neurodegeneration.”
BackgroundResultSelf-citationApplications of diffusion‐weighted and diffusion tensor MRI to white matter diseases – a review
Horsfield, M. A., & Jones, D. K. (2002) · NMR in Biomedicine · doi:10.1002/nbm.787 · Cited by 468
Bacioglu, M., Maia, L. F., Preische, O., Schelle, J., Apel, A., Kaeser, S. A., Schweighauser, M., Eninger, T., Lambert, M., Pilotto, A., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.018 · Cited by 435
White matter damage in Alzheimer disease and its relationship to gray matter atrophy
Agosta, F., Pievani, M., Sala, S., Geroldi, C., Galluzzi, S., Frisoni, G. B., & Filippi, M. (2011) · Radiology · doi:10.1148/radiol.10101284 · Cited by 288 · cited 1×
“Although AD has traditionally been viewed as a disease of the gray matter (Amlien and Fjell, 2014), several studies employing neuroimaging modalities have provided evidence of both macroand microstructural white matter abnormalities during the course of the disease (Agosta et al., 2011; Liu et al., 2009; Mayo et al.,…”
BackgroundJanelidze, S., Hertze, J., Nägga, K., Nilsson, K., Nilsson, C., Wennström, M., van Westen, D., Blennow, K., Zetterberg, H., & Hansson, O. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.11.017 · Cited by 237 · cited 1×
“, 2015) and AD dementia (Janelidze et al., 2017; Skillbäck et al., 2017), as well as in mouse models of Ab pathology (Montagne et al.”
BackgroundSelf-citationAmlien, I. K., & Fjell, A. M. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.02.017 · Cited by 219
Cerebrospinal fluid -amyloid 1-42 concentration may predict cognitive decline in older women
Gustafson, D. R., Skoog, I., Rosengren, L., Zetterberg, H., & Blennow, K. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.100529 · Cited by 214
Self-citationSkoog, I., Davidsson, P., Aevarsson, Ó., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000068478 · Cited by 194
Self-citationGold, B. T., Johnson, N. F., Powell, D. K., & Smith, C. D. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.07.009 · Cited by 170 · cited 1×
“These findings are in line with those from the present study, in which the concentration of NfL in CSF was negatively associated with FA and positively associated with MD in widespread white matter regions, suggesting that increased concentration of NfL in CSF reflect increased white matter damage (Gold et al., 2012).”
ResultHviid, C. V. B., Knudsen, C. S., & Parkner, T. (2020) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2020.1730434 · Cited by 143
Myelin changes at the early stage of 5XFAD mice
Gu, L., Wu, D., Tang, X., Qi, X., Li, X., Bai, F., Chen, X., Ren, Q., & Zhang, Z. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.12.013 · Cited by 87 · cited 1×
“Importantly, in 5 FAD mice, the concentration of NfL in CSF was around 15 times higher compared to non-tg littermates already at 2 months of age, the time point at which myelin abnormalities and decreased axonal caliber have been reported (Gu et al., 2018), and the first extracellular Ab plaques start to accumulate in…”
BackgroundNeurofilament relates to white matter microstructure in older adults
Moore, E. E., Hohman, T. J., Badami, F. S., Pechman, K. R., Osborn, K. E., Acosta, L. M. Y., Bell, S. P., Babicz, M. A., Gifford, K. A., Anderson, A. W., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.06.023 · Cited by 65 · cited 1×
“Furthermore, in CU subjects and prodromal AD, associations between NfL in CSF and DTI measurements of white matter microstructure were recently described (Moore et al., 2018).”
BackgroundSelf-citation
Cited by
Xia, D., Lianoglou, S., Sandmann, T., Calvert, M., Suh, J. H., Thomsen, E., Dugas, J., Pizzo, M. E., DeVos, S. L., Earr, T. K., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00547-7 · Cited by 124
“5-2 fold) was within the range of what has been reported in patients with mild-cognitive impairment and AD [101, 102] and contrasted with the profound elevation of Nf-L levels in CSF reported in the 5xFAD and APP/PS1 mouse models (~10-20 fold) [101, 102], indicating that AppSAA mice may better recapitulate the rate of…”
Das, S., Dewit, N., Jacobs, D., Pijnenburg, Y. A. L., In ‘t Veld, S. G. J. G., Coppens, S., Quaglia, M., Hirtz, C., Teunissen, C. E., & Vanmechelen, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137221 · Cited by 26
“An increase in CSF Nf-L levels in an individual over time is inherent to normal aging, and, in line with previous findings, we reported in this cohort that Nf-L levels increased with the increasing age of patients [13,30,31].”
ResultAging: What We Can Learn From Elephants
Chusyd, D. E., Ackermans, N. L., Austad, S. N., Hof, P. R., Mielke, M. M., Sherwood, C. C., & Allison, D. B. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.726714 · Cited by 23
“, 2019), AD rodent models (Bacioglu et al., 2016; Andersson et al., 2020), and cognitive dysfunction in dogs (Panek et al.”
Background
Metadata
- Authors
- Andersson, E., Janelidze, S., Lampinen, B., Nilsson, M., Leuzy, A., Stomrud, E., Blennow, K., Zetterberg, H., & Hansson, O.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 95
- Pages
- 143-153
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W3044853761
- Cited by
- 79
- References
- 29
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.